Humana Inc

Latest Results (24.10.2025):

Humana Inc. reported its second quarter of 2025 financial results, demonstrating strong earnings performance and updating its full-year guidance. The company raised its adjusted earnings per share (EPS) and revenue expectations for the full year, reflecting confidence in its strategic initiatives and operational excellence.

Earnings Performance

In Q2 2025, Humana reported a GAAP earnings per share (EPS) of $4.51 and an adjusted EPS of $6.27. Year-to-date EPS stood at $14.81 on a GAAP basis and $17.85 on an adjusted basis, showcasing robust profitability.

Insurance Segment Benefit Ratio

The Insurance segment maintained a benefit ratio of 89.9% in Q2 2025, aligning with the company's guidance of approximately 90%. This stability reflects effective management of healthcare costs and claims.

Full Year 2025 Guidance

Humana raised its full-year 2025 adjusted EPS guidance to approximately $17.00, up from $16.25, and increased its consolidated revenue forecast to at least $128 billion, exceeding the previous range of $126 billion to $128 billion.

Membership Guidance

For individual Medicare Advantage, Humana now anticipates a decline of up to 500,000 members in 2025, slightly better than the earlier forecast of approximately 550,000. This adjustment accounts for the exit of certain unprofitable plans and counties while maintaining confidence in the company's pricing strategy.

Strategic Expansion

Humana continues to expand its footprint in CenterWell and Medicaid. Key achievements include CenterWell Pharmacy gaining access to 17 new limited distribution drugs, CenterWell Primary Care projecting higher patient growth, and the launch of a new Medicaid contract in Virginia, opening up dual special needs plan (D-SNP) opportunities.